GlobeNewswire

VITEC to Showcase Field-Proven Military and Defense Video Streaming Solutions at DSEI

Dela

PARIS, July 25, 2017 (GLOBE NEWSWIRE) -- VITEC, a leader in advanced video encoding and streaming solutions, today announced it will demonstrate its broad range of point-to-point streaming and full motion video (FMV) solutions engineered for mission-critical and tactical military and defense operations at stand N7-350 at DSEI from Sept. 12-15 at ExCeL in London.

"VITEC's latest encoding solutions and IPTV management system are designed to allow military personnel to easily disseminate live feeds and recorded video assets in various bit-rates optimized for the specific network link available, whether stationary or in the field," said Mark Rushton, business development manager, VITEC.

VITEC will highlight its MGW Pico TOUGH, the world's smallest, most power-efficient MIL-STD-certified H.264 HD/SD encoding solution and streaming appliance. Weighing less than 400 grams, Pico TOUGH sets a new standard of performance for manned and unmanned airborne platforms, military vehicles, and ground units, packing all the needed capabilities for any Surveillance, Intelligence, and Reconnaissance (ISR) sensor or Situational Awareness video in an ultra-small airborne and marine-certified enclosure. The Pico TOUGH consumes less than 7 watts of power for 1080p encoding with KLV STANAG 4609 metadata and features simultaneous, low-latency streaming of two sources from HD-SDI and analog composite signals, JITC-compliant metadata processing, AES encryption, reliable transport/error correction technology, real-time resolution scaling, image cropping, and full-size snapshot capture. The rugged enclosure uses MIL-DTL-38999 connectors and is certified for extreme environmental conditions.

Also on display will be VITEC's MGW Ace Encoder and Decoder, the industry's first entirely portable, hardware-based end-to-end 4:2:2 10-bit HEVC encode/decode solution. The powerful yet compact MGW Ace encoder provides pristine video quality with its HEVC (H.265) bandwidth-efficient compression as well as legacy H.264 encoding capabilities. With a wide selection of I/Os and low power consumption using VITEC's proprietary second-generation HEVC Codec (GEN2), it's the perfect solution for streaming video, audio, and KLV metadata while in the field or on the move with, up to 50 percent bandwidth savings compared to today's H.264 standards. The MGW Ace Decoder features a robust, portable enclosure suited for field use and provides best-in-class video quality over rich and industry-standard audio/video connectivity. For point-to-point applications, when paired with the MGW Ace Decoder, the solution delivers bandwidth-efficient, error-free video streaming over any network, including the internet, with embedded Pro-MPEG FEC or Zixi(TM) error-correction capabilities.

VITEC will also showcase its FITIS (Fully Integrated Tactical IPTV System), an FMV solution for capturing, processing, archiving, indexing, managing, and disseminating tactical ISR video and metadata. Designed for rapid deployments and efficient distribution of IP video across LANs and WANs and in any network configuration, it enables real-time playback of tactical and situational awareness imagery, continuous recording and indexing of metadata, and retrieval of vital video assets and analysis notes. It supports propagation of scenario-specific video imagery in a variety of formats and bandwidth constraints from high-definition ISR footage for analysts, to ultra-compressed streams for transmission to tactical units at the edge.

About VITEC
VITEC is a leading worldwide end-to-end video streaming solutions provider for broadcast, military and government, enterprise, sports and entertainment venues, and houses of worship. © 2017 VITEC

PR Link:  www.ingearpr.com/VITEC/170725VITEC.docx  

Image Link:  www.ingearpr.com/VITEC/VITEC_Pico_TOUGH.zip 
Caption: VITEC Pico TOUGH

Image Link:  http://www.ingearpr.com/VITEC/VITEC_MGW-ACE-Pair.jpg
Caption: VITEC Point-to-Point HEVC Streaming

Image Link: FITIS:  www.ingearpr.com/VITEC/VITEC_FITIS.jpg 
Caption: VITEC FITIS 

Media Contact:
Peggy Blaze
InGear 
Tel: +1 (818) 357-3693
Email: peggy@ingearpr.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: VITEC via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum